German High-Grade Non-Hodgkin´s Lymphoma Study Group (DSHNHL) Selected Research

4-demethoxyanthracycline

1/2014

Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

German High-Grade Non-Hodgkin´s Lymphoma Study Group (DSHNHL) Research Topics

Disease

1	Lymphoma (Lymphomas) 01/2014
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2014
1	Drug-Related Side Effects and Adverse Reactions 01/2014
1	Cardiotoxicity 01/2014

Drug/Important Bio-Agent (IBA)

1	4-demethoxyanthracyclineIBA 01/2014
1	Rituximab (Mabthera)FDA Link 01/2014
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2014
1	Daunorubicin (Cerubidine)FDA LinkGeneric 01/2014
1	Etoposide (VP 16)FDA LinkGeneric 01/2014
1	Prednisone (Sone)FDA LinkGeneric 01/2014
1	Vincristine (Oncovin)FDA LinkGeneric 01/2014
1	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 01/2014
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2014